Washington: An effective cure for inflammatory skin conditions like eczema is a step closer to reality, researchers say.
Scientists have found that a strain of yeast implicated in skin conditions like eczema, can be killed by certain peptides and could provide a new treatment for these debilitating skin conditions.
20 percent of children in the UK suffer from atopic eczema and whilst this usually clears up in adolescence, 7 percent of adults will continue to suffer throughout their lifetime.
Furthermore, this type of eczema, characterized by dry, itchy, flaking skin, is increasing in prevalence. Whilst the cause of eczema remains unknown, one known trigger factor is the yeast Malassezia sympodialis.
This strain of yeast is one of the most common skin yeasts in both healthy individuals and those suffering from eczema. The skin barrier is more fragile and often broken in those suffering from such skin conditions, and this allows the yeast to cause infection, which then further exacerbates the condition.
Scientists at Karolinska Institute in Sweden looked for a way to kill Malassezia sympodialis without harming healthy human cells.
The researchers looked at the effect on the yeast of 21 peptides that had either; cell-penetrating or antimicrobial properties.
Cell-penetrating peptides are often investigated as drug delivery vectors and are able to cross the cell membrane, although the exact mechanism for this is unknown.
Antimicrobial peptides, on the other hand, are natural antibiotics and kill many different types of microbe including some bacteria, fungi and viruses.
Tina Holm and her colleagues added these different peptides types to separate yeast colonies and assessed the toxicity of each peptide type to the yeast.
They found that six of the 21 peptides they tested, successfully killed the yeast without damaging the membrane of keratinocytes, human skin cells.
“Many questions remain to be solved before these peptides can be used in humans,” Holm said.
“However, the appealing combination of being toxic to the yeast at low concentrations whilst sparing human cells makes them very promising as antifungal agents.”
“We hope that these peptides in the future can be used to ease the symptoms of patients suffering from atopic eczema and significantly increase their quality of life,” she added.
The study was recently published in the Society for Applied Microbiology’s journal, Letters in Applied Microbiology.
ANI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.